The Global Single-use Bioprocessing Market size is expected to reach $53.8 billion by 2028, rising at a market growth of 16.0% CAGR during the forecast period.
A significant amount of pre-commercial scale, that is, clinical and preclinical, biopharmaceutical manufacturing, now uses single-use or disposable bioprocessing equipment, and this practice is spreading to the production of commercial goods.
In many ways, single-use bioprocessing systems will eventually dominate much of the creation of biopharmaceuticals, especially at smaller scales, as they now predominate the pre-commercial market and are trending toward higher use for commercial-scale manufacturing. Fixed stainless steel systems will continue to be used in the majority of commercial biopharmaceutical manufacturing, especially for high-volume pharmaceuticals, as they are frequently still economically more viable at scales.
However, single-use facilities will eventually take over the bioprocessing industry in terms of the number of facilities, process lines, products produced, and labor done by bioprocessing professionals, particularly at clinical scales. For the research and production of pharmaceutical goods like monoclonal antibodies, vaccines, customized medicine, and others, single-use bioprocessing uses disposable technologies.
During the creation of several biopharmaceuticals and drug development phases, the use of single-use bioprocessing products has increased significantly. This innovation has made medication manufacturing more efficient, straightforward, and affordable both upstream and downstream. The market for single-use bioprocessing is expected to develop as a result of factors such as the rise in disposable technology adoption, the rising need for biopharmaceuticals, the reduced risk of product cross-contamination associated with SUB technologies, and the need for less floor space.
The initiatives heavily rely on single-use technologies since they are adaptable, economical, and less likely to cause cross-contamination. It is projected that the COVID-19 pandemic will continue to enhance the usage of these bioprocessing systems and fuel business expansion. Single-use manufacturers have expanded their production facilities worldwide as a result of the commercial success of biopharmaceuticals. Furthermore, many firms' multi-year strategies have included capacity expansion initiatives as a way to take advantage of their worldwide reach and larger client bases. Owing to this, the spread of COVID-19 pandemic has positively affected the growth of single use bioprocessing market.
One in six persons worldwide will be over 65 by 2050 (16%), up from one in eleven (9%), according to data from the UN. By 2050, there will be 426 million people who are 80 years of age or older, which is expected to quadruple the current population of 143 million. The demand for biopharmaceuticals is anticipated to rise as the senior population grows across key markets since the aged are more susceptible to chronic illnesses & conditions.
Emerging nations such as China and India offer great growth opportunities. This is mainly because these countries have a skilled labor force and access to favorable government backing, growing private investments, rising desire to outsource to developing markets. It's possible that industry participants will find new sources of income in such nations. The significant infrastructure investment in biomanufacturing is also a key factor in these sectors' high expansion potential. This investment was made to meet the rising need for the production of vaccines and biologics.
In recent years, the development of bioprocesses and the production of biopharmaceuticals have both embraced single-use technology to a large extent. Even though the advantages of these technologies are well acknowledged, there are serious worries about extractables and leachables that come from single-use systems due to their possible impact on product quality and patient health. Before implementing disposable technologies into manufacturing, it is important to understand how they will affect the quality and safety of drug products.
Based on product, the single-use bioprocessing market is segmented into simple & peripheral elements, apparatus & plants, and work equipment. In 2021, the simple & peripheral elements segment dominated the single-use bioprocessing market with maximum revenue share. This is due to ongoing improvements in these products and the rising importance of bioprocessing operations in the overall manufacturing process. The simple & peripheral elements segment was dominated by filters, tubing, connectors, and transfer systems since most single-use vendors offer tubing and connections in a format that is compatible with bioreactors, single-use bags, or other single-use bioprocessing equipment.
On the basis of workflow, the single-use bioprocessing market is fragmented into upstream bioprocessing, fermentation and downstream bioprocessing. In 2021, the upstream bioprocessing segment held the largest revenue share in the single-use bioprocessing market. This is because of the ongoing improvements and advances in upstream bioprocessing technology. For instance, cutting-edge technologies like the micro-bioreactor system offer automated experimental setup and sampling in addition to high-throughput upstream process development, efficient cell culture processing, and media & feed optimization.
By end use, the single-use bioprocessing market is divided into biopharmaceutical manufacturers and academic & clinical research institutes. The academic & clinical research institutes segment recorded a significant revenue share in the single-use bioprocessing market in 2021. The implementation of these technologies in academic and research institutions has been hastened by the development of benchtop scale bioprocessing equipment and single-use system technology.
| Report Attribute | Details |
|---|---|
| Market size value in 2021 | USD 19.1 Billion |
| Market size forecast in 2028 | USD 53.8 Billion |
| Base Year | 2021 |
| Historical Period | 2018 to 2020 |
| Forecast Period | 2022 to 2028 |
| Revenue Growth Rate | CAGR of 16% from 2022 to 2028 |
| Number of Pages | 408 |
| Number of Tables | 664 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Competitive Landscape, Companies Strategic Developments, Company Profiling |
| Segments covered | Product, Workflow, End-use, Region |
| Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
| Growth Drivers |
|
| Restraints |
|
Region use, the single-use bioprocessing market is analyzed across North America, Europe, Asia Pacific and LAMEA. In 2021, the North America region led the single-use bioprocessing market by generating the highest revenue share. This could be the region's established pharmaceutical and biomanufacturing sector and extensive R&D efforts. Similar to this, the need for single-use bioprocessing equipment is fueled by a growing emphasis on vaccine production to support local efforts at disease prevention.
Free Valuable Insights: Global Single-use Bioprocessing Market size to reach USD 53.8 Billion by 2028
The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Danaher Corporation, 3M Company, Thermo Fisher Scientific, Inc. are the forerunners in the Single-use Bioprocessing Market. Companies such as Merck Millipore, Boehringer Ingelheim International GmbH, Corning Incorporated are some of the key innovators in Single-use Bioprocessing Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include 3M Company, Boehringer Ingelheim International GmbH, Corning Incorporated, Danaher Corporation, Eppendorf SE, Merck Millipore (Merck KGaA), Entegris, Inc., Sartorius Stedim Biotech S.A. (Sartorius AG), Thermo Fisher Scientific, Inc., and Avantor, Inc.
By Product
By End-use
By Workflow
By Geography
The global Single-use Bioprocessing Market size is expected to reach $53.8 billion by 2028.
Rising Need For Biopharmaceuticals are driving the market in coming years, however, Leachables And Extractables-Related Issues restraints the growth of the market.
3M Company, Boehringer Ingelheim International GmbH, Corning Incorporated, Danaher Corporation, Eppendorf SE, Merck Millipore (Merck KGaA), Entegris, Inc., Sartorius Stedim Biotech S.A. (Sartorius AG), Thermo Fisher Scientific, Inc., and Avantor, Inc.
The Biopharmaceutical Manufacturers segment is leading the Global Single-use Bioprocessing Market by End-use in 2021 thereby, achieving a market value of $31.8 billion by 2028.
The North America market dominated the Global Single-use Bioprocessing Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $19.3 billion by 2028.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 